缓释口服曲前列地尼治疗肺动脉高压的临床应用

IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE
S. Pugliese, T. Bull
{"title":"缓释口服曲前列地尼治疗肺动脉高压的临床应用","authors":"S. Pugliese, T. Bull","doi":"10.2147/IBPC.S68230","DOIUrl":null,"url":null,"abstract":"The development of parenteral prostacyclin therapy marked a dramatic breakthrough in the treatment of pulmonary arterial hypertension (PAH). Intravenous (IV) epoprostenol was the first PAH specific therapy and to date, remains the only treatment to demonstrate a mortality benefit. Because of the inherent complexities and risks of treating patients with continuous infusion IV therapy, there is great interest in the development of an oral prostacyclin analog that could mimic the benefits of IV therapy. Herein, we highlight the development of oral prostacyclin therapy, focusing on oral treprostinil, the only US Food and Drug Administration approved oral prostacyclin. Recent Phase III clinical trials have shown the drug to improve exercise tolerance in treatment-naïve PAH patients, but not patients on background oral therapy. Oral treprostinil appears to be most efficacious at higher doses, but its side effect profile and complexities with dosing complicate its use. While oral treprostinil’s current therapeutic role in PAH remains unclear, ongoing studies of this class of medication should help clarify their role in the treatment of PAH.","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"9 1","pages":"1 - 7"},"PeriodicalIF":1.5000,"publicationDate":"2016-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S68230","citationCount":"10","resultStr":"{\"title\":\"Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension\",\"authors\":\"S. Pugliese, T. Bull\",\"doi\":\"10.2147/IBPC.S68230\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The development of parenteral prostacyclin therapy marked a dramatic breakthrough in the treatment of pulmonary arterial hypertension (PAH). Intravenous (IV) epoprostenol was the first PAH specific therapy and to date, remains the only treatment to demonstrate a mortality benefit. Because of the inherent complexities and risks of treating patients with continuous infusion IV therapy, there is great interest in the development of an oral prostacyclin analog that could mimic the benefits of IV therapy. Herein, we highlight the development of oral prostacyclin therapy, focusing on oral treprostinil, the only US Food and Drug Administration approved oral prostacyclin. Recent Phase III clinical trials have shown the drug to improve exercise tolerance in treatment-naïve PAH patients, but not patients on background oral therapy. Oral treprostinil appears to be most efficacious at higher doses, but its side effect profile and complexities with dosing complicate its use. While oral treprostinil’s current therapeutic role in PAH remains unclear, ongoing studies of this class of medication should help clarify their role in the treatment of PAH.\",\"PeriodicalId\":45299,\"journal\":{\"name\":\"Integrated Blood Pressure Control\",\"volume\":\"9 1\",\"pages\":\"1 - 7\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2016-01-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/IBPC.S68230\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Integrated Blood Pressure Control\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/IBPC.S68230\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrated Blood Pressure Control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IBPC.S68230","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 10

摘要

前列环素肠外治疗的发展标志着肺动脉高压(PAH)治疗的重大突破。静脉注射(IV)丙烯醇是PAH的第一种特异性治疗方法,迄今为止,也是唯一一种证明降低死亡率的治疗方法。由于持续静脉输注治疗患者固有的复杂性和风险,人们对开发一种口服前列环素类似物产生了极大的兴趣,这种类似物可以模仿静脉输注治疗的益处。在此,我们强调口服前列环素治疗的发展,重点是口服曲前列素,这是美国食品和药物管理局唯一批准的口服前列环素。最近的III期临床试验表明,该药可以改善treatment-naïve PAH患者的运动耐受性,但对口服治疗的患者无效。口服曲前列替尼在高剂量时似乎最有效,但其副作用和剂量复杂性使其使用复杂化。虽然口服曲前列尼目前在多环芳烃中的治疗作用尚不清楚,但对这类药物的持续研究应有助于阐明其在治疗多环芳烃中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
The development of parenteral prostacyclin therapy marked a dramatic breakthrough in the treatment of pulmonary arterial hypertension (PAH). Intravenous (IV) epoprostenol was the first PAH specific therapy and to date, remains the only treatment to demonstrate a mortality benefit. Because of the inherent complexities and risks of treating patients with continuous infusion IV therapy, there is great interest in the development of an oral prostacyclin analog that could mimic the benefits of IV therapy. Herein, we highlight the development of oral prostacyclin therapy, focusing on oral treprostinil, the only US Food and Drug Administration approved oral prostacyclin. Recent Phase III clinical trials have shown the drug to improve exercise tolerance in treatment-naïve PAH patients, but not patients on background oral therapy. Oral treprostinil appears to be most efficacious at higher doses, but its side effect profile and complexities with dosing complicate its use. While oral treprostinil’s current therapeutic role in PAH remains unclear, ongoing studies of this class of medication should help clarify their role in the treatment of PAH.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Integrated Blood Pressure Control
Integrated Blood Pressure Control PERIPHERAL VASCULAR DISEASE-
CiteScore
4.60
自引率
0.00%
发文量
13
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信